This study found that choosing second-line therapy on the basis of a protein-expression test modestly improved survival in patients with advanced non-small cell lung cancer (NSCLC). The four- to six-week survival advantage held up in a sensitivity analysis involving 10,000 simulations. Choosing second-line therapy on the basis of a protein-expression test modestly improved survival in patients with advanced non-small cell lung cancer (NSCLC), computer modeling suggested.
Use of the test to decide whether to give a patient an epidermal growth factor receptor (EGFR) inhibitor led to a predicted survival of 10 months versus eight to nine months with three conventional decision-making strategies. Read more at MedPage Today.